维得利珠单抗治疗合并原发性硬化性胆管炎与炎症性肠病患者:不改善肝脏生化指标,但对肠道疾病安全有效
这项回顾性多中心研究纳入34例合并原发性硬化性胆管炎(PSC)与炎症性肠病(IBD)的成人患者,评估维得利珠单抗对肝脏生化及肠道疾病活动的影响。第30周血清碱性磷酸酶中位数无总体变化(基线268 IU/L vs 第30周249 IU/L,P=0.99),其他肝脏生化及Mayo PSC风险评分亦无显著变化;第30周临床缓解率克罗恩病为55%、溃疡性结肠炎为29%。结论认为维得利珠单抗不改善肝脏生化,但与肠道疾病改善相关且安全性良好。
要点
- 维得利珠单抗治疗期间血清碱性磷酸酶中位数无总体变化(基线268 IU/L vs 第30周249 IU/L,P=0.99)。
- 第30周临床缓解率克罗恩病为55%、溃疡性结肠炎为29%。
- 7例(21%)停用维得利珠单抗,其中6例因IBD持续活动、1例因肝脏生化恶化。
核心结论
- 维得利珠单抗治疗合并PSC与IBD的患者未改善肝脏生化指标,但与肠道疾病改善相关且安全性良好。
研究设计与样本
- 回顾性多中心研究,纳入确诊IBD合并PSC的成人患者34例(克罗恩病16例、溃疡性结肠炎18例),其中9例(26%)有肝移植史。
- 主要结局为第14周和第30周血清碱性磷酸酶水平变化,次要结局包括其他肝脏生化指标及肠道疾病临床结局变化,并分析不良事件安全性。
主要发现
- 血清碱性磷酸酶中位数无总体变化:基线268(IQR 105-551)IU/L vs 第30周249(IQR 183-634)IU/L,P=0.99。
- 第30周其他肝脏生化指标及Mayo PSC风险评分均无显著变化。
- 第30周临床缓解率:克罗恩病55%,溃疡性结肠炎29%。
- 维得利珠单抗中位随访9个月(IQR 7-16)。
- 7例(21%)停用维得利珠单抗:6例因IBD持续活动,1例因肝脏生化恶化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Blocking of lymphocyte trafficking to bile ducts is a potential mechanism to alter the disease course of patients with primary sclerosing cholangitis (PSC). AIM: To describe the effect of the α4 β7 integrin antibody, vedolizumab, on liver biochemistry and disease activity in patients with PSC and inflammatory bowel disease (IBD). METHODS: This is a retrospective multi-centre study of adult patients with a diagnosis of both IBD and PSC. The primary outcome was change in serum alkaline phosphatase level at weeks 14 and 30. Secondary outcomes included changes in other liver biochemistries and in clinical outcomes for the bowel disease. A safety analysis for adverse events was performed. RESULTS: Thirty-four patients (16 Crohn's disease, 18 ulcerative colitis) were included. Nine (26%) had a history of liver transplant. Median follow-up on vedolizumab was 9 months (IQR: 7-16). There was no overall change in serum alkaline phosphatase level with vedolizumab therapy (median 268 [IQR: 105-551] IU/L at baseline versus 249 [IQR: 183-634] IU/L, P = 0.99 at week 30). No significant changes in other liver biochemistries or the Mayo PSC Risk Score were demonstrated at week 30. Clinical remission was achieved at week 30 in 55% of Crohn's disease and 29% of ulcerative colitis patients. Seven (21%) patients ceased vedolizumab; six patients stopped therapy due to persistent IBD activity and one for worsening of liver biochemistries. CONCLUSION: Vedolizumab treatment in patients with PSC and IBD did not improve liver biochemistry but was associated with improvement in bowel disease and a favourable safety profile.
引用
- Christensen B, Micic D, Gibson PR, et al. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018. PMID: 29377235. doi:10.1111/apt.14525
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。